Last reviewed · How we verify
PDE5 inhibitor (tadalafil)
PDE5 inhibitor (tadalafil) is a PDE5 inhibitor Small molecule drug developed by Regina Elena Cancer Institute. It is currently in Phase 3 development for Cancer therapy (investigational; specific indication unclear from available information).
Tadalafil inhibits phosphodiesterase type 5 (PDE5), increasing cyclic GMP levels to promote vasodilation and smooth muscle relaxation.
Tadalafil inhibits phosphodiesterase type 5 (PDE5), increasing cyclic GMP levels to promote vasodilation and smooth muscle relaxation. Used for Cancer therapy (investigational; specific indication unclear from available information).
At a glance
| Generic name | PDE5 inhibitor (tadalafil) |
|---|---|
| Sponsor | Regina Elena Cancer Institute |
| Drug class | PDE5 inhibitor |
| Target | PDE5 (phosphodiesterase type 5) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PDE5 inhibitors block the enzyme that degrades cyclic guanosine monophosphate (cGMP), allowing cGMP to accumulate in vascular and smooth muscle tissues. This leads to increased vasodilation and improved blood flow. In the context of cancer therapy at Regina Elena Cancer Institute, tadalafil may be investigated for its potential to enhance tumor perfusion, improve drug delivery, or modulate the tumor microenvironment.
Approved indications
- Cancer therapy (investigational; specific indication unclear from available information)
Common side effects
- Headache
- Dyspepsia
- Flushing
- Myalgia
- Nasal congestion
- Back pain
Key clinical trials
- Tadalafil 5 mg on Storage Lower Urinary Tract Symptoms After Anatomical Endoscopic Enucleation of the Prostate (PHASE1)
- Phosphodiesterase Type 5 Inhibitors in Patients With Group 2 Pulmonary Hypertension (NA)
- Trial of Tadalafil, Tamsulosin and Combination for Access Sheath Deployment (PHASE4)
- Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH (PHASE2)
- Efficacy and Tolerability of Tadalafil Versus Darifenacin in Management of Ureteric Stent-Related LUTS (PHASE1, PHASE2)
- Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PHASE3)
- Solifenacin Plus Tadalafil vs Solifenacin Alone for Overactive Bladder in Females (NA)
- COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PDE5 inhibitor (tadalafil) CI brief — competitive landscape report
- PDE5 inhibitor (tadalafil) updates RSS · CI watch RSS
- Regina Elena Cancer Institute portfolio CI
Frequently asked questions about PDE5 inhibitor (tadalafil)
What is PDE5 inhibitor (tadalafil)?
How does PDE5 inhibitor (tadalafil) work?
What is PDE5 inhibitor (tadalafil) used for?
Who makes PDE5 inhibitor (tadalafil)?
What drug class is PDE5 inhibitor (tadalafil) in?
What development phase is PDE5 inhibitor (tadalafil) in?
What are the side effects of PDE5 inhibitor (tadalafil)?
What does PDE5 inhibitor (tadalafil) target?
Related
- Drug class: All PDE5 inhibitor drugs
- Target: All drugs targeting PDE5 (phosphodiesterase type 5)
- Manufacturer: Regina Elena Cancer Institute — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Cancer therapy (investigational; specific indication unclear from available information)